Diabetic foot ulcers: Retrospective comparative analysis from Sicily between two eras.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 28 06 2021
accepted: 18 10 2021
entrez: 7 12 2021
pubmed: 8 12 2021
medline: 7 1 2022
Statut: epublish

Résumé

The aim of this study was to analyze changes in the incidence, management and mortality of DFU in Sicilian Type 2 diabetic patients hospitalized between two eras, i.e. 2008-2013 and 2014-2019. We compared the two eras, era1: 2008-13, era2: 2014-19. In era 1, n = 149, and in era 2, n = 181 patients were retrospectively enrolled. In the population hospitalized for DFU in 2008-2013, 59.1% of males and 40.9% of females died, whilst in 2014-2019 65.9% of males and 34.1% of females died. Moderate chronic kidney disease (CKD) was significantly higher in patients that had died than in ones that were alive (33% vs. 43%, p < 0.001), just as CKD was severe (14.5% vs. 4%, p < 0.001). Considering all together the risk factors associated with mortality, at Cox regression multivariate analysis only moderate-severe CKD (OR 1.61, 95% CI 1.07-2.42, p 0.021), age of onset greater than 69 years (OR 2.01, 95% CI 1.37-2.95, p <0.001) and eGFR less than 92 ml/min (OR 2.84, 95% CI 1.51-5.34, p 0.001) were independently associated with risk of death. Patients with DFU have high mortality and reduced life expectancy. Age at onset of diabetic foot ulcer, eGFR values and CKD are the principal risk factors for mortality.

Identifiants

pubmed: 34874944
doi: 10.1371/journal.pone.0259405
pii: PONE-D-21-21103
pmc: PMC8651101
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0259405

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Diabetes Metab Syndr Obes. 2020 May 25;13:1835-1842
pubmed: 32547145
Diabetes Metab Syndr. 2019 May - Jun;13(3):1727-1732
pubmed: 31235085
N Engl J Med. 2017 Jun 15;376(24):2367-2375
pubmed: 28614678
Am J Clin Dermatol. 2020 Apr;21(2):255-264
pubmed: 31848923
Angiology. 2020 Apr;71(4):303-314
pubmed: 31884807
Diabet Med. 2019 Nov;36(11):1424-1430
pubmed: 31150130
BMC Public Health. 2020 Jan 10;20(1):41
pubmed: 31924173
BMC Endocr Disord. 2019 Jan 3;19(1):1
pubmed: 30606164
Int Wound J. 2019 Dec;16(6):1339-1346
pubmed: 31418528
Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3273
pubmed: 32176445
Diabetes Care. 2020 Feb;43(2):487-493
pubmed: 31857443
J Vasc Surg. 2020 Feb;71(2):669-681.e2
pubmed: 31676182
Int J Endocrinol. 2018 Mar 15;2018:7631659
pubmed: 29736169
Eur Heart J Cardiovasc Pharmacother. 2020 Apr 1;6(2):115-121
pubmed: 31873726
Diabetes Care. 2019 Jan;42(Suppl 1):S124-S138
pubmed: 30559237
Diabet Med. 2019 Aug;36(8):995-1002
pubmed: 31004370
Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3269
pubmed: 32176451
Microvasc Res. 2020 Jul;130:103987
pubmed: 32035919
J Acute Med. 2019 Jun 1;9(2):59-63
pubmed: 32995232
Diabetes Care. 2008 Jul;31(7):1288-92
pubmed: 18390801
PLoS One. 2019 May 29;14(5):e0216832
pubmed: 31141534
Diabet Med. 2018 May 23;:
pubmed: 29791033
J Vasc Surg. 2005 Feb;41(2):269-78
pubmed: 15768009
Nutr Metab Cardiovasc Dis. 2020 Feb 10;30(2):167-178
pubmed: 31848052
Ann Vasc Surg. 2016 May;33:149-58
pubmed: 26907372
Bol Med Hosp Infant Mex. 2020;77(6):293-302
pubmed: 33186343
Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3249
pubmed: 32176443
Burns Trauma. 2020 Jul 06;8:tkaa017
pubmed: 32685563
JAMA Intern Med. 2017 Oct 1;177(10):1498-1505
pubmed: 28873137
N Engl J Med. 2020 Apr 23;382(17):1629-1637
pubmed: 32320570
Curr Atheroscler Rep. 2017 Oct 2;19(11):44
pubmed: 28971322
Eur J Intern Med. 2011 Jun;22(3):266-74
pubmed: 21570646
Diabetes Care. 2018 Apr;41(4):645-652
pubmed: 29559450
Eur J Intern Med. 2020 Dec;82:1-6
pubmed: 32972800
Clin Sci (Lond). 2020 Jun 26;134(12):1399-1401
pubmed: 32556177
Expert Opin Biol Ther. 2017 Aug;17(8):979-987
pubmed: 28532226
Eur J Clin Invest. 2004 Dec;34(12):785-96
pubmed: 15606719

Auteurs

Valentina Guarnotta (V)

Sezione di Malattie Endocrine, del Ricambio e della Nutrizione, Dipartimento di Promozione della Salute, Materno-Infantile, Medicina Interna e Specialistica di Eccellenza "G. D'Alessandro" (PROMISE), Università di Palermo, Palermo, Italy.

Stefano Radellini (S)

Sezione di Malattie Endocrine, del Ricambio e della Nutrizione, Dipartimento di Promozione della Salute, Materno-Infantile, Medicina Interna e Specialistica di Eccellenza "G. D'Alessandro" (PROMISE), Università di Palermo, Palermo, Italy.

Enrica Vigneri (E)

Sezione di Malattie Endocrine, del Ricambio e della Nutrizione, Dipartimento di Promozione della Salute, Materno-Infantile, Medicina Interna e Specialistica di Eccellenza "G. D'Alessandro" (PROMISE), Università di Palermo, Palermo, Italy.

Achille Cernigliaro (A)

Osservatorio Epidemiologico, Dipartimento Salute, Regione Sicilia, Italia.

Felicia Pantò (F)

Sezione di Malattie Endocrine, del Ricambio e della Nutrizione, Dipartimento di Promozione della Salute, Materno-Infantile, Medicina Interna e Specialistica di Eccellenza "G. D'Alessandro" (PROMISE), Università di Palermo, Palermo, Italy.

Salvatore Scondotto (S)

Osservatorio Epidemiologico, Dipartimento Salute, Regione Sicilia, Italia.

Piero Luigi Almasio (PL)

Sezione di Gastroenterologia ed Epatologia, Dipartimento di Promozione della Salute, Materno-Infantile, Medicina Interna e Specialistica di Eccellenza "G. D'Alessandro", PROMISE, Università degli Studi di Palermo, Palermo, Italy.

Giovanni Guercio (G)

Sezione di Chirurgia d'Urgenza, Dipartimento di Chirurgia, Oncologia e Scienza Orale, DICHIRONS, Università degli Studi di Palermo, Palermo, Italy.

Carla Giordano (C)

Sezione di Malattie Endocrine, del Ricambio e della Nutrizione, Dipartimento di Promozione della Salute, Materno-Infantile, Medicina Interna e Specialistica di Eccellenza "G. D'Alessandro" (PROMISE), Università di Palermo, Palermo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH